• With the addition of 2,176 NVIDIA Blackwell GPUs, Roche now operates the pharmaceutical industry’s largest announced hybrid-cloud AI factory, totaling more than 3,500 GPUs. 
• The new computational infrastructure supports Roche’s vision of building an AI-accelerated healthcare organisation.
• NVIDIA AI factories help accelerate discoveries, enable more efficient clinical trials, and unlock data insights at scale, ultimately advancing innovation and improved healthcare outcomes.

Roche has announced an expansion of its global AI infrastructure, building a large-scale AI system powered by the latest NVIDIA accelerated computing technologies.

The setup includes 2,176 high-performance GPUs installed on-site in the United States and Europe and integrated across its operations. The aim is to speed up the development of diagnostics and new treatments. With this latest investment, Roche now operates more than 3,500 Blackwell GPUs across its on-premise and cloud systems — the largest announced GPU capacity in the pharmaceutical industry.

This computational expansion marks the next phase of a strategic NVIDIA collaboration that started in 2023. By leveraging NVIDIA AI infrastructure, Roche accelerates drug development through high-quality data and groundbreaking AI.

“In healthcare, time is the most critical variable; every day saved means a life-changing medicine or diagnostic reaches a patient sooner,” said Wafaa Mamilli, Roche’s Chief Digital and Technology Officer.

“Our AI factory combines world-class computing power with Roche’s scientific expertise to embed AI across the entire value chain — from discovery to development, manufacturing and commercialisation — transforming how we deliver the next generation of medicines and diagnostics solutions.”

Roche’s AI factory is a high-performance supercomputing platform that powers digital transformation across the organisation. In R&D, the NVIDIA BioNeMo platform enhances Roche’s Lab-in-the-Loop, where biological and chemistry experiments are connected with Roche’s AI models.

This helps scientists test hypotheses at scale, accelerate progress, and make discoveries that were not possible otherwise. In manufacturing, digital twins — virtual replicas of production lines — powered by NVIDIA Omniverse libraries, allow engineers to op timize processes and factory designs.

In diagnostics, accelerated computing and NVIDIA Parabricks software enable insights across vast datasets. In digital pathology, the technologies scan a large number of images to detect subtle disease patterns. In digital health, Roche uses NVIDIA NeMo Guardrails to ensure safe and reliable healthcare-grade conversational AI. 

“Our expanded collaboration with NVIDIA and the launch of this AI factory further strengthens our leadership in AI-driven drug discovery and development,” said Aviv Regev, Executive Vice President and Head of Genentech Research and Early Development (gRED).

“By providing the massive computational power needed to continue to scale our Lab-in-the-Loop strategy — a space we have pioneered for over five years — our scientists can build m ore sophisticated predictive frontier models and further shorten the path from biological insight to life-saving medicine.” 

Artificial Intelligence at Roche 
The implementation of the AI factory is a cornerstone of Roche’s broader digital transformation. For Roche, AI is a key capability designed to augment or complement human expertise.

By expanding access to supercomputing capabilities across the organisation, the company empowers its global workforce to tackle the most complex challenges in human disease. Roche’s vision for AI is fundamentally about accelerating the journey toward preventing, stopping, and curing diseases.